With these comments in mind, targeting dysregulated IL-17 signaling pathway seems to be a new area of promising immunotherapy for AILD patients, especially for those patients who failed to respond to conventional therapy. Here, IL17A is linked to angioimmunoblastic T-cell lymphoma.